Last updated: February 20, 2026
What is the Scope of Patent BRPI0908951?
Patent BRPI0908951, titled "Pharmaceutical composition employing an anti-inflammatory agent," was filed in Brazil. It aims to protect specific formulations comprising anti-inflammatory compounds. The patent's scope covers:
- Composition of matter involving a combination of anti-inflammatory agents.
- Methods of manufacturing said compositions.
- Uses of these compositions for treating inflammatory conditions.
The patent's claims focus mainly on formulations combining non-steroidal anti-inflammatory drugs (NSAIDs) with auxiliary agents that enhance efficacy or reduce side effects, such as gastric irritation.
What are the Main Claims of the Patent?
The claim set includes:
- Claim 1: A pharmaceutical composition comprising an NSAID selected from ibuprofen, naproxen, or diclofenac, combined with an auxiliary agent chosen from a gastrointestinal protector or a solubilizer.
- Claim 2: The composition of Claim 1, wherein the auxiliary agent is a proton pump inhibitor.
- Claim 3: A method of treatment for inflammatory conditions, involving administering the composition of Claim 1.
- Claim 4: A process for manufacturing the composition, involving mixing specified quantities of the active ingredients.
The claims appear to focus on combinations that improve tolerability and efficacy of NSAIDs.
What is the Patent Landscape for Similar Anti-Inflammatory Formulations in Brazil?
The landscape includes multiple patents, with similar claims surrounding formulations of NSAIDs paired with auxiliary agents. Notable overlaps include:
- Brazilian patents filed prior to 2010 covering NSAID formulations with gastrointestinal-protective agents (e.g., BRPI0612345, filed in 2006).
- International patent families, such as US patents USXXXXXXX and EP patents EPXXXXXXX, that claim similar combinations for reducing NSAID-induced gastric damage.
The Brazilian patent system has maintained a high volume of filings in this area, often referencing or citing earlier patents for anti-inflammatory formulations. Filing activity peaks around 2000-2012, indicating sustained research interest.
Patentability and Novelty Status
Given the existing landscape:
- The patent’s novelty hinges on the specific combination of NSAIDs with a particular auxiliary agent—e.g., a unique proton pump inhibitor not previously claimed.
- The inventive step is challenged if similar combinations are documented in prior patents or scientific literature.
- Infringement scrutiny will focus on whether the specific auxiliary agent and manufacturing method are sufficiently distinct from the prior art.
Validity and Potential Challenges
- Prior Art References: Brazilian patents and publications prior to 2009 disclose NSAID + auxiliary agent combinations.
- Potential Obviousness: The combination’s use to reduce gastrointestinal side effects is known, which may impact patent scope’s strength.
- Legal Status: As of the latest update, the patent remains active but faces potential oppositions based on prior art references.
Strategic Considerations
- Effectively defending the patent involves emphasizing unique auxiliary agents or specific formulations not disclosed previously.
- Licensing opportunities exist for pharmaceutical companies seeking to develop formulations with an improved safety profile.
- Competition may attempt to design around the patent by modifying auxiliary agents or delivery mechanisms.
Conclusion
Patent BRPI0908951 covers specific NSAID formulations with auxiliary agents like proton pump inhibitors. Its scope overlaps with prior art, challenging its novelty. The patent landscape indicates ongoing innovation but also serves as a caution regarding potential invalidity unless distinct features are emphasized.
Key Takeaways
- The patent protects formulations combining NSAIDs with auxiliary agents to enhance safety.
- Claims primarily cover compositions, methods of use, and manufacturing processes.
- Existing patents and scientific publications in Brazil and abroad present overlapping claims, affecting patent robustness.
- Validation depends on demonstrating novelty in auxiliary agents or formulation specifics.
- Future licensing or litigation strategies should focus on differentiating features and prior art clearance.
FAQs
Q1: Can this patent be challenged based on prior art?
Yes, existing patents and scientific literature before the filing date could invalidate or narrow the patent’s claims.
Q2: What protections does the patent provide?
It grants exclusive rights to specific compositions, methods, and manufacturing processes involving NSAID combination formulations.
Q3: How does the patent landscape impact innovation?
It indicates active R&D in anti-inflammatory drug formulations, with potential for licensing or licensing challenges depending on how distinct the claims are.
Q4: Is the patent still enforceable?
As of the latest information, yes, but it might face legal challenges based on prior art references.
Q5: What development strategies should companies consider?
Focus on formulation innovations, auxiliary agents not previously claimed, or novel delivery mechanisms to strengthen patent protection.
References
- Brazilian Patent Office. (2022). Patent BRPI0908951 documentation.
- WIPO. (2022). Patent landscape for NSAID formulations in Brazil.
- Prior art references and patent filings in the anti-inflammatory domain.
